ArticleTherapeutic advances in medical oncology2021

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).

Hye Sook Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.